Bristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors. According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and […]
PsiOxus Therapeutics
Alphatec shuffles the deck | Personnel Moves, Sept. 19, 2016
Alphatec shuffles the deck Alphatec (NSDQ:ATEC) said it returned chairman Leslie Cross to the corner office as interim CEO, effective Sept. 16, and made a few other changes in the executive suite. Cross, who was Alphatec’s CEO from 2012 to 2014, succeeded the resigning James Corbett, Carlsbad, Calif.-based Alphatec said. The company also promoted COO Michael […]
